For millions of individuals who have undergone massive weight loss, body contouring procedures—particularly panniculectomy—represent a life-changing milestone. By removing excess, sagging skin and tissue from the abdomen, these surgeries alleviate chronic rashes, infections, and mobility limitations, effectively transitioning from "cosmetic" to "functional" medicine. However, a groundbreaking study published in the November issue of Plastic and Reconstructive Surgery® has introduced a critical new variable into the preoperative risk assessment process: a history of COVID-19.
According to researchers at the Penn State College of Medicine, patients with a previous COVID-19 infection face a significantly higher risk of developing venous thromboembolism (VTE) following a panniculectomy. As the medical community continues to navigate the long-term physiological aftermath of the global pandemic, this finding suggests that the hypercoagulable state—a tendency for blood to clot more easily—associated with COVID-19 may persist long after the initial infection has cleared, necessitating a reevaluation of surgical safety protocols.
The Scope of the Study: Examining the Post-Pandemic Patient
To determine whether COVID-19 serves as an independent risk factor for VTE, the research team conducted a comprehensive analysis of national hospital data covering the years 2017 to 2023. The study cohort consisted of 7,114 patients who underwent functional panniculectomy.
To ensure the data reflected the evolving landscape of healthcare, the researchers divided the participants into two distinct timeframes: those who underwent surgery prior to the onset of the pandemic and those who underwent the procedure afterward. The researchers observed that, in aggregate, the rates of VTE remained stable across both periods—3.2% before March 2020 and 3.0% afterward. However, this high-level view masked a more concerning reality hidden within the post-pandemic subgroup.
When the researchers isolated the 4,099 patients who underwent surgery after March 2020, they compared the 790 patients who had a documented history of COVID-19 against the 3,309 patients who did not. The results were stark: the incidence of VTE among those with a history of COVID-19 reached 4.9%, compared to just 2.5% in those who had never contracted the virus. This represents a nearly twofold increase in risk, even when accounting for other comorbidities such as heart, lung, and vascular disease, which remained balanced across both groups.
Understanding the Medical Risks: What is VTE?
Venous thromboembolism is an umbrella term for two severe, life-threatening conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs when a blood clot forms in a deep vein, typically in the legs. If that clot breaks free and travels to the lungs, it becomes a pulmonary embolism, which can cause severe respiratory distress, cardiac strain, and, in fatal cases, sudden death.
In the context of major reconstructive surgeries like panniculectomy, where extensive tissue is removed, the body is already under physiological stress. Surgeons typically utilize the "Caprini score"—a standardized clinical tool used to assess a patient’s risk of developing VTE—to determine the necessity of prophylactic anticoagulants (blood thinners) and mechanical devices like compression stockings. The findings from the Penn State study suggest that the current Caprini model may be incomplete, as it does not currently account for the specific vascular damage or systemic inflammation caused by a past COVID-19 infection.
The Physiology of Hypercoagulability
The researchers hypothesize that the increased VTE rate is likely driven by the systemic inflammatory response triggered by SARS-CoV-2. COVID-19 is well-documented for its ability to induce endothelial dysfunction—damage to the lining of the blood vessels—and to activate the body’s coagulation pathways. Even in patients who have recovered from mild or asymptomatic cases, these microscopic vascular changes may persist, creating a "pro-thrombotic" environment.
"Our results demonstrate a significant increase in the incidence of VTE among panniculectomy patients with a history of COVID-19," the authors noted. The data suggests that for these patients, the surgical trauma of a panniculectomy acts as a secondary trigger, compounding the existing, sub-clinical clotting tendency left behind by the virus.
Clinical Implications: A Paradigm Shift in Patient Care
The implications for the plastic surgery community are profound. As the backlog of elective and functional surgeries continues to be addressed in the post-pandemic era, surgeons must now integrate a patient’s COVID-19 status into their preoperative consultation.
1. Updated Preoperative Screening
Currently, surgeons screen for BMI, smoking status, age, and pre-existing chronic conditions. The inclusion of "COVID history" as a distinct screening question could prove vital. Clinicians may need to establish a timeline, perhaps investigating if the time elapsed since the infection correlates with the risk, or if certain variants posed higher long-term risks than others.
2. Tailoring Prophylaxis
If a patient with a history of COVID-19 is identified as higher risk, surgeons may consider more aggressive prophylaxis. This could include longer durations of anticoagulation therapy post-surgery, closer monitoring during the first 48 to 72 hours, or the use of more intensive mechanical compression devices.
3. Shared Decision-Making
Plastic surgeons often pride themselves on the collaborative relationship they build with patients, particularly those who have undergone major weight loss. This study provides a concrete data point that can be used in informed consent discussions, allowing patients to understand the specific risks they face and the steps their surgical team is taking to mitigate them.
The Future of Research: Moving Beyond the Initial Findings
While the study provides a robust signal, the authors are the first to emphasize that this is a starting point rather than a definitive final word. As lead author Mary Newland, a medical student at Penn State, points out, "This may have implications for assessment and prevention of surgical risks of body contouring surgery after major weight loss."
The next steps for the medical community include:
- Large-Scale Longitudinal Studies: Researchers hope to determine if the VTE risk plateaus after a certain period of recovery from COVID-19.
- Biomarker Research: Investigating whether specific markers of inflammation or coagulation in the blood could serve as better predictors of VTE risk than a simple self-reported history of COVID-19.
- Refining the Caprini Score: There is an ongoing debate within the surgical community regarding whether to formally update the Caprini assessment tool to include COVID-19 as a weighted factor.
Official Stance and Conclusion
The American Society of Plastic Surgeons (ASPS) continues to prioritize patient safety through the dissemination of evidence-based research published in Plastic and Reconstructive Surgery®. By highlighting these risks, the journal provides practitioners with the tools necessary to adapt their practice to the realities of a post-pandemic world.
For patients considering a panniculectomy, the message is not to avoid surgery, but to ensure that their surgical team is fully aware of their medical history, including any past bouts with COVID-19. As we gain a deeper understanding of the lingering effects of the virus, the surgical community’s ability to adapt and protect its patients remains a testament to the rigorous, data-driven nature of modern reconstructive medicine.
About the Study
The study, "Incidence of Postoperative Venous Thromboembolism following Panniculectomy in Patients with History of COVID-19," was authored by Mary Newland, BS, and colleagues. It appears in the November 2025 issue of Plastic and Reconstructive Surgery (DOI: 10.1097/PRS.0000000000012202).
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) remains a global leader in professional information and software solutions, supporting healthcare providers with the latest research to improve patient outcomes. Headquartered in the Netherlands, the organization continues to facilitate the publication of peer-reviewed data that helps medical professionals worldwide make critical, evidence-based decisions.
About the Author
